Celtic merges funds to create Anglo-Russian newco promising free medicines to Africa
This article was originally published in Scrip
Executive Summary
Celtic Pharma Holdings, the private equity group, is merging the assets of its CP2 and CP3 funds to create Pro Bono Bio, a new pharmaceutical holding company launched 12 September. The new company will run a business model that will allow it to sell healthcare products at prices aligned with an economy's ability to pay. Pro Bono will hit the ground running as it will also launch a nanotech-based product, Flexiseq, to treat osteoarthritic pain, in the UK, using contract sales organisations and it will conduct further launches in the following months.
You may also be interested in...
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Despite BMS Bid, Celgene Pays $75m Upfront For Immatics Assets Options
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.